Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P (REG S)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 220.00 141 08:00:00
Bid Price Offer Price High Price Low Price Open Price
210.00 230.00 220.00 220.00 220.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -0.42 -1.00 131
Last Trade Time Trade Type Trade Size Trade Price Currency
08:09:06 O 141 226.19 GBX

Renalytix Ai (RENX) Latest News

More Renalytix Ai News
Renalytix Ai Takeover Rumours

Renalytix Ai (RENX) Discussions and Chat

Renalytix Ai Forums and Chat

Date Time Title Posts
31/3/202007:35RenalytixAI : AI solutions for Kidney disease detection, care and drug discovery137

Add a New Thread

Renalytix Ai (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-04-08 15:20:35226.302,1454,854.14O
2020-04-08 15:01:10220.005,00011,000.00O
2020-04-08 15:00:49226.401,9874,498.57O
2020-04-08 14:58:08226.504,4159,999.98O
View all Renalytix Ai trades in real-time

Renalytix Ai (RENX) Top Chat Posts

Renalytix Ai Daily Update: Renalytix Ai Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix Ai was 220p.
Renalytix Ai Plc has a 4 week average price of 173.50p and a 12 week average price of 173.50p.
The 1 year high share price is 372p while the 1 year low share price is currently 120p.
There are currently 59,416,134 shares in issue and the average daily traded volume is 56,932 shares. The market capitalisation of Renalytix Ai Plc is £130,715,494.80.
wan: I note today's RNS Non-Regulatory, that a very key/influential individual has been recruited. hTTps://
wan: My interpretation of the need and use of Placing, which was "significantly oversubscribed with strong demand received from existing and new shareholders", was to accelerate matters, this has now been confirmed in last nights announcement - James McCullough, CEO of RenalytixAI, commented: "We are pleased to have achieved an oversubscribed placing supported by a broad range of investors, and thank them for their support. The Company will now be better resourced to support the acceleration of its commercial plans, having made rapid progress against its objectives as set out at the time of its IPO in November 2018." hTTps://
pugugly: The Company is pleased to confirm that relevant EKF shareholders on the register as at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held. Entitlements will be rounded down to the nearest whole number of RENX Shares and fractional entitlements will be aggregated and sold in the open market with the net proceeds donated to charity, in line with the Company's articles.
the stigologist: The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector. Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past." The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC). Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m However when considering how to value Physiomics it's important to realise there are two major strands to it's business. One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m) The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS. e.g. Oesophagal Cancer study hTtps:// Prostate Cancer study hTtps:// This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m. Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m. In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.
Renalytix Ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 07:37:40